XML 26 R15.htm IDEA: XBRL DOCUMENT
v3.22.1

Note 9 - Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2021
Notes to Financial Statements |
Income Tax Disclosure [Text Block] | Note 9 – Income Taxes At December 31, 2021, the Company had $1,671,893 of federal research and development tax credits. If not utilized, the research and development tax credits expire from 2028-2040. For the year ended December 31, 2021 and 2020, the Company has provided a full valuation allowance against all of the net deferred tax assets in the amount of $2,990,093 and $3,381,133, respectively. This was based on management’s assessment, including the last two years of operating losses, that it is more likely than not that the net deferred tax assets may not be realized in the future. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was enacted by the United States Congress. As a result of the enactment of the CARES Act, net operating losses (“NOL’s”) generated in 2018-2020 can now be carried back for five years and resulted in the Company recognizing approximately $1.5 million of a tax benefit, of which $.7 million is a receivable at December 31, 2021. We continue to evaluate for potential utilization of the Company’s deferred tax asset, which has been fully reserved for, on a quarterly basis, reviewing our economic models, including projections and timing of orders, the commencement of operations of the CVD Materials segment and cost containment measures. The expense/(benefit) for income taxes includes the following:
|  | 2021 |  |  | 2020 |
Current: |  |  |  |  |  |  |  |
Federal |  | $ | 14,978 |  |  | $ | (1,528,305 | )
State |  |  | 13,399 |  |  |  | 950 |
Total current tax provision |  |  | 28,377 |  |  |  | (1,527,355 | )
Deferred: |  |  |  |  |  |  |  |
Federal |  |  | - |  |  |  | - |
State |  |  | --- |  |  |  | --- |
Total deferred tax provision |  |  | - |  |  |  | - |
Income tax expense / (benefit) |  | $ | 28,377 |  |  | $ | (1,527,355 | )
The tax effects of temporary differences giving rise to significant portions of the net deferred taxes are as follows:
|  | 2021 |  |  | 2020 |
Deferred income tax assets: |  |  |  |  |  |  |  |
Allowance for doubtful accounts |  | $ | 12,926 |  |  | $ | 35,442 |
Inventory capitalization |  |  | 6,620 |  |  |  | 6,969 |
Impairment Charge |  |  | 722,720 |  |  |  | 712,683 |
Research & development tax credits |  |  | 1,671,893 |  |  |  | 1,719,598 |
Compensation costs |  |  | 148,958 |  |  |  | 211,363 |
Vacation accrual |  |  | 141,079 |  |  |  | 89,626 |
Interest expense carryforward |  |  | - |  |  |  | 223,768 |
Net operating loss carryforward |  |  | 808,163 |  |  |  | 925,912 |
Other items |  |  | 94,235 |  |  |  | 12,248 |
Total deferred tax asset |  |  | 3,606,594 |  |  |  | 3,937,609 |
Deferred incomes tax liability: |  |  |  |  |  |  |  |
Property and equipment - tax over book depreciation |  |  | (616,501 | ) |  |  | (556,476 | )
Less valuation allowance |  |  | (2,990,093 | ) |  |  | (3,381,133 | )
Net long-term deferred tax asset |  | $ | - |  |  | $ | - |
The reconciliation of the federal statutory income tax rate to our effective tax rate is as follows:
|  | 2021 |  |  | 2020 |
Expected provision at federal statutory tax rate (21%) |  | $ | 1,002,721 |  |  | $ | (1,596,485 | )
PPP loan forgiveness |  |  | (513,118 | ) |  |  | - |
Provision for valuation allowance |  |  | (346,209 | ) |  |  | 883,796 |
Foreign tax (income) loss |  |  | (115,863 | ) |  |  | 70,492 |
Net operating loss carryback |  |  | - |  |  |  | (1,527,355 | )
State taxes, net of federal benefit |  |  | 5,787 |  |  |  | (36,832 | )
Federal research & development credit |  |  | (56,761 | ) |  |  | (64,266 | )
Other permanent differences |  |  | 51,820 |  |  |  | 743,295 |
Income (benefit) / tax expense |  | $ | 28,377 |  |  | $ | (1,527,355 | )
The Company’s foreign subsidiary, CVD Tantaline ApS recognized income (loss) of approximately $552,000 and ($336,000) for the years ended December 31, 2021 and 2020, respectively. Based on the standard corporate tax rate of 22% in Denmark, the Company would have incurred a tax expense (benefit) in the amount of $121,000 and ($74,000) for the years ended December 31, 2021 and 2020, respectively, however, as sufficient uncertainty exists as to the realization of these assets, a full valuation allowance is necessary for the losses incurred prior to December 31, 2021.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 17 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 270 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -URI http://asc.fasb.org/topic&trid=2144680 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration